CIPO Patents = 1

EPO Patents = 3

Trademarks = 2

Forward Citations = 17

Loading Chart...

1 inventor (with patents filed for the assignee):

Lawrence S Zisman (6 out of 9 patents)

6 patents: Sort by Forward Citations

1. 11364238 - Combination therapy for treating pulmonary hypertension (2022-06-21),

2. 10532994 - Non-selective kinase inhibitors (2020-01-14),

3. 10246438 - Non-selective kinase inhibitors (2019-04-02),

4. 10231966 - Combination therapy for treating pulmonary hypertension (2019-03-19),

5. 9925184 - Spray-dry formulations (2018-03-27),

6. 9815815 - Non-selective kinase inhibitors (2017-11-14),

Company Overview

Pulmokine, Inc. is a biopharmaceutical company focused on developing innovative therapies for respiratory diseases. Our mission is to improve the lives of patients with serious lung conditions through the discovery and development of new treatments. With a dedicated team of researchers and scientists, we are committed to advancing the science of pulmonary medicine and bringing novel therapies to market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

6 Patents

#12 in Troy, NY

#2,695 in New York

#44,981 in US

Troy, NY, United States of America

Pulmokine, Inc.

Forward Citations = 17

1 inventor:

Lawrence S Zisman (6 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pulmokine, Inc.. Retrieved from https://idiyas.com/company/pulmokine

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

1 patent (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]